Updates - Rare Coalition

Rare Disease Company Coalition (RDCC) Urges Passage of Continuing Resolution to Reauthorize Rare Pediatric Disease Priority Review Voucher Program

RDCC Comments on Advancing Rare Disease Therapies Through a FDA Rare Disease Innovation Hub

Rare Disease Biotech Innovators Urge Timely Reauthorization of Rare Pediatric Disease Priority Review Voucher (PRV) Program

RDCC’s Response to 21st Century Cures Act and Cures 2.0 Request for Information

RDCC Submits Response to Senator Cassidy’s Request for Information on “Improving Americans’ Access to Gene Therapies”

ORPHAN Cures Act Enables Rare Disease Companies to Pursue Promising Research to Uncover More Treatment Options

RDCC Participates in FDA Rare Disease Day 2023 Public Meeting

Hopes, Fears for Orphan Drug Act

Vital Health Podcast: The Accelerated Approval Pathway is Vital for Rare Disease Treatments

RARECast Podcast: Examining the Legislative Landscape for Rare Disease Drug Development

Groups Hope New Congress Will Pass Bipartisan Bills Centered on Rare Diseases

New Study Finds Patient Access to Rare Disease Drugs Would Decline Sharply Under Proposals to Limit Medicaid Reimbursements

RDCC Joins in Call for Repeal of R&D Tax Policy that Hurts Rare Disease Innovation

RDCC Joins in Support of “Newborn Screening Saves Lives Reauthorization Act of 2021” in Letter to Senate Leaders

RDCC Advocates for “Newborn Screening Saves Lives Reauthorization Act of 2021” in Letter to Congressional Leaders

Cutting the Orphan Drug Tax Credit is Not Drug Pricing Reform

Rare Disease Drugmakers to Congress: Don’t Gut the Accelerated Approval Pathway

Drug Makers To Congress: Reject Accelerated Approval Pay Reforms

Rare Disease Companies Unite to Advocate for Life-Changing Therapies